GlassScriptPhysician profile
Troy H Dillard
NPI 1730351529
$25,340.61
in general payments reported to CMS, 2019-2025
24 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $6,835 · 2021: $13.58 · 2022: $345 · 2023: $682 · 2024: $656 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,235 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.32 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $12,446.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,247.01 | 2019-2020 | |
| Abbott Laboratories | $493.85 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Novo Nordisk INC | $334.03 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic, INC. | $272.33 | 2022-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $242.68 | 2019-2022 | |
| Beta Bionics, INC. | $237.77 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amgen INC. | $217.38 | 2023-2025 | Evenity, Tepezza, Prolia |
| Xeris Pharmaceuticals, INC. | $155.50 | 2022-2025 | Gvoke Hypopen, Keveyis, Recorlev |
| Tandem Diabetes Care, INC. | $130.31 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $76.11 | 2023-2024 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $68.95 | 2025 | Twiist |
| Horizon Therapeutics Plc | $47.22 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $45.99 | 2022 | |
| Nevro Corp. | $42.89 | 2023 | Senza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.91 | 2022-2023 | |
| Amphastar Pharmaceuticals, INC. | $40.79 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $39.21 | 2023 | Isturisa, Signifor Lar |
| Verity Pharmaceuticals INC. | $35.66 | 2025 | Tlando |
| Astellas Pharma US INC | $31.50 | 2024 | Veozah |
| Medtronic Minimed, INC. | $24.92 | 2020 | |
| Averitas Pharma INC. | $23.56 | 2023 | Qutenza |
| Ascendis Pharma Endocrinology INC | $22.97 | 2025 | Yorvipath |
| Insulet Corporation | $22.42 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Dillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.